Day Trading Gap Algorithm
Real Time Cell Phone / Email Swing Trade Alerts
Stocks Gapping Down 2017-04-21
ADMP Adamis Pharmaceuticals Corporation (ADMP) intends to offer to sell shares of its common stock in an underwritten public offering.
GNMX Aevi Genomic Medicine (GNMX) will present today at the World Congress on ADHD on results from the SAGA study assessing lead product candidate AEVI-001. Shares plummeted last month after the company announced it failed to beat placebo in adolescents with mGluR mutation-positive ADHD.
APRI Apricus Biosciences (APRI) priced an underwritten public offering of more than 5 million units at $1.40 each. Each unit consists of one share of Apricus common stock and one warrant to purchase 0.75 of a share of common stock. The warrants will expire five years from the date they are first exercisable, and have an exercise price of $1.55 per share. Apricus' gross proceeds from this offering are expected to be approximately $7 million and will be used to fund a resubmission of its new drug application for Vitaros and for general corporate purposes and working capital.
BEBE bebe stores (BEBE) said in a regulatory filing it expects to close all its store by the end of May. It said it expects to recognize an impairment charge of approximately $20 million, net of deferred rent and other credits, as a result of closing the stores. This impairment charge will be recorded in Q3 and Q417.
EFII Electronics for Imaging (EFII) reported Q1 EPS of $0.55, in-line with the analyst estimate of $0.55. Revenue for the quarter came in at $228.7 million versus the consensus estimate of $239.22 million.
NYSE:FMSA Fairmount Santrol (NYSE:FMSA) Barclays downgrades Fairmount Santrol from Overweight to Equal-Weight.
GPT Gramercy Property Trust (GPT) commenced an underwritten public offering of 9,000,000 common shares. In connection with the offering, the Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 1,350,000 common shares.
HAS Hasbro (HAS) down in sympathy of Mattel negative earnings report.
MANH Manhattan Associates, Inc. (MANH) reported Q1 EPS of $0.42, $0.04 better than the analyst estimate of $0.38. Revenue for the quarter came in at $143.5 million versus the consensus estimate of $146.49 million. GUIDANCE: Manhattan Associates, Inc. sees FY2017 EPS of $1.89-$1.93, versus the consensus of $1.91. Manhattan Associates, Inc. sees FY2017 revenue of $606-620 million, versus the consensus of $624.7 million.
MAT Mattel (MAT) reported Q1 EPS of $0.32, $0.49 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $735.6 million versus the consensus estimate of $804.82 million.
MXIM Maxim Integrated Products (MXIM) reported Q3 EPS of $0.56, $0.03 better than the analyst estimate of $0.53. Revenue for the quarter came in at $581 million versus the consensus estimate of $575.73 million. GUIDANCE: Maxim Integrated Products sees Q4 2017 EPS of $0.59-$0.65, versus the consensus of $0.58. Maxim Integrated Products sees Q4 2017 revenue of $590-630 million, versus the consensus of $597.81 million.
FIZZ National Beverage (FIZZ) Credit Suisse downgrades National Beverage from Outperform to Neutral.
ONTX Onconova Therapeutics (ONTX) said late Thursday it intends to offer and sell shares of its common stock in an underwritten public offering. Onconova also expects to grant to the underwriter for the offering a 45-day option to purchase an additional 15% of the shares of common stock offered in the public offering. Onconova said it intends to use net proceeds to support development of rigosertib for treatment in higher risk myelodysplastic syndromes.
SHOO Steven Madden (SHOO) said Friday its Q1 adjusted net earnings per share was $0.47, compared to the unadjusted reported earnings of $0.39 a year ago, and beating Capital IQ analysts' expectations of $0.43 per share. The company said in a press release it had net sales in Q1 of $366.4 million, up from $329.4 million in the same period a year ago and above analysts' consensus expectation of $359.5 million. The company said it expects net sales for 2017 to be up 8% to 10% from 2016, and adjusted EPS to be $2.12 to $2.18. Analysts are expecting FY EPS of $2.17.
SYRS Syros Pharmaceuticals (SYRS) said it privately placed almost 2.6 million shares at $13.50 per share with several institutional accredited investors. The purchase price for the shares represents an 8.8% discount to the average closing price of the company's common stock over the 30 trading days prior to the entry into the stock purchase agreement. The private placement is expected to close on or about April 26.
TXMD TherapeuticsMD Inc (TXMD) Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against TherapeuticsMD, Inc.
XBIT XBiotech (XBIT) said it is not likely to receive European marketing approval for its colorectal treatment antibody when a committee votes in May. The company said the European Medicines Agency rendered a negative trend vote after meeting to discuss the Day 180 list of outstanding issues. The vote means it is unlikely that a positive Committee for Medicinal Products for Human Use opinion will be attained at the formal decision vote and additional steps will need to be taken. The key outstanding issues are related to clinical relevance of the therapy in the indication and quality assurance related matters, the company said.
Copyright dailystockplays.com All Rights Reserved